Does Semax help with anxiety?
Yes, in animal studies. Semax has a documented anxiolytic – anxiety-reducing – effect. However, the evidence is purely preclinical. And the effect strongly depends on the animal's baseline emotional state. It does not appear uniformly under all conditions. This point is of great importance. In one study, researchers analysed normal, non-stressed conditions. Semax did not alter the animals' emotional state at all. There was no measurable effect on anxiety when anxiety was not already elevated [1]. However, the researchers tested a different scenario. They used cholecystokinin-tetrapeptide (CCK-4) to artificially induce anxiety. This compound reliably causes anxiety and panic-like reactions. Under these conditions, Semax normalised disturbed behaviour. It showed a clear anxiolytic and antidepressant effect – but only when anxiety was already elevated [1].
The same pattern also appears in studies of chronic administration. No initial effect. A significant effect in elevated anxiety. When Semax was administered daily for one to two weeks to normal rats, it elicited measurable anxiolytic and antidepressant effects. It did not significantly alter exploratory activity in a non-stressful environment [2]. Researchers proposed a mechanism. They suggested that the effect worked by activating the brain's serotonin system. Increased production of BDNF in the hippocampus likely also played a role [2].
Co dzieje się z lękiem specyficznie w warunkach przewlekłego stresu?
The strongest evidence for Semax's anxiolytic properties comes from models of chronic stress. In these studies, the peptide reversed several markers of prolonged stress exposure.
One study used a chronic unpredictable stress protocol. This is a standard way of simulating prolonged psychological stress in animals. Semax reversed several things. It reversed stress-induced anhedonia – the loss of the ability to feel pleasure. This is closely linked to both anxiety and depression. Semax also prevented stress-related suppression of weight gain. It reduced the enlargement of the adrenal glands, a marker of chronic overactivation of stress hormones. And it restored hippocampal BDNF levels that stress had reduced [3]. A separate study confirmed similar effects using the same stress model [4].
Another study analysed the genetic response to acute stress. Researchers administered Semax 30 minutes prior to a stressful restraint procedure. It significantly reduced stress-induced behavioural changes in rats. Over 1500 genes in the hippocampus changed their expression pattern as a result [5]. This correction reversed the disruptions caused by stress itself. This tells us something important. The anxiety-reducing effect is not merely a behavioural change. It is linked to a genuine molecular correction at the gene level.
Semax affects anxiety at a brain level by influencing the neurochemical pathways involved in stress and mood regulation. It is believed to modulate the levels of neurotransmitters such as dopamine, serotonin, and norepinephrine, which play a crucial role in reducing stress responses and promoting a sense of calm. Additionally, Semax has been shown to promote neurogenesis and neuroprotection, potentially improving the brain's resilience to stress and reducing anxiety-related symptoms.
Semax appears to reduce stress-related activation in brain regions involved in processing fear and threat.
Researchers analysed rats with different natural predispositions to emotional stress. Semax injection reduced stress-induced c-Fos gene activation. This gene is a marker of recent nerve cell activity. The reduction occurred specifically in the hypothalamic paraventricular nucleus and the medial septum. Both areas are central to the stress response. This effect was observed in animals naturally predisposed to anxiety [6]. Semax also reduced stress-induced c-Fos activity in the lateral septum and the basolateral amygdala. The amygdala is a major centre for fear and threat detection in the brain [6]. This pattern offers a plausible biological explanation. It helps explain the anxiety-reducing behavioural effects seen elsewhere.
Functional connectivity research has added human evidence. Researchers analysed healthy human volunteers using brain imaging. They examined how Semax affected communication between the amygdala and other brain regions. They observed measurable changes in amygdala-related connectivity after Semax administration [7]. This study did not use a formal measure of anxiety symptoms. However, it does support the idea that Semax affects anxiety-related brain circuits in humans.
Jak szybko Semax pomaga na lęk?
Research into chronic administration revealed something specific. Anxiolytic effects developed over one to two weeks of daily dosing [2]. They did not appear immediately after a single dose. This suggests that Semax's anti-anxiety benefits build up gradually. They do not act as an immediate sedative. This fits with the underlying mechanism. Serotonin activity and BDNF production change gradually. These are processes that unfold over days to weeks, not instantaneously.
Has there been any human evidence for Semax and anxiety?
Direct human evidence is limited. A functional connectivity brain imaging study included 52 healthy participants. It showed that Semax affects amygdala-related brain connectivity [7]. This is useful background information. However, the study did not measure clinical symptoms of anxiety, nor did it use validated anxiety questionnaires.
No published clinical trials have tested Semax as a treatment for diagnosed anxiety disorders in humans. The evidence is mechanistically encouraging. But for anxiety specifically, it remains firmly in the animal study phase.
Does Semax help with depression?
Semax exhibits antidepressant-like effects in animal models of depression. The most convincing evidence comes from the chronic unpredictable stress model. This is one of the standard, well-validated ways of modelling depression-like states in animals.
In this study, chronic treatment with a low dose of Semax reversed several key features of a depression-like state. These features were induced by prolonged unpredictable stress in male rats. Semax reversed anhedonia – measured by reduced preference for a sugar-water solution. It reversed body mass suppression. It reversed adrenal gland enlargement. And it reversed reduced hippocampal BDNF levels [3]. Reduced hippocampal BDNF is one of the most consistently replicated findings in depression research across species. Semax's ability to restore it here is therefore significant.
Researchers also compared Semax with Melanotan II in the same study. Melanotan II is a stronger activator of the same melanocortin receptor pathway. Both compounds elicited similar antidepressant effects at low doses [3]. This suggests that the antidepressant action may occur via the melanocortin receptors common to both compounds. However, neither compound affected immobility duration in the forced-swim test. This is another standard measure in antidepressant studies. Therefore, the antidepressant profile was not uniform across all tests [3].
Does Semax work as a clinical antidepressant?
A direct scientific commentary on this topic has appeared. A commentary from 2008, titled „Therapeutic opportunity of 'Semax’ application in depression,” posed exactly this question in the psychiatric literature [8]. It reflects genuine scientific interest in Semax's antidepressant potential.
However, this was merely commentary. It discussed possibility and rationale, not actual patient data. No controlled clinical trials have tested Semax as a treatment for clinical depression. This remains true to this day.
How does Semax affect mood more broadly?
A study of chronic administration in unstressed rats yielded something noteworthy. Semax induced measurable antidepressant effects even without an imposed depression model. It also concurrently produced anxiolytic effects. The researchers attributed both to two things: activation of serotonergic brain systems and increased production of BDNF in the hippocampus [2].
The known effects of Semax on serotonin are also relevant here. It increases serotonin turnover in the striatum. This is confirmed by elevated levels of 5-HIAA, a breakdown product of serotonin, which persist for several hours after administration [9]. Increased serotonergic activity is a common target for most conventional antidepressants. Semax achieves this effect via a completely different pharmacological route than SSRIs, but the end point overlaps.
The related study offers an interesting perspective. Young rats were exposed early in life to the SSRI antidepressant fluvoxamine. This disrupted their later anxiety-like behaviour, learning ability, and biogenic amine levels. Subsequent treatment with Semax reduced the resulting anxiety-like behaviour. It improved learning. And normalised the disrupted brain chemical levels [10]. This suggests Semax may help correct mood and behavioural disorders stemming from early serotonin system disturbances—even in a developmental context very different from adult depression.
Is Semax or Selank better for depression?
Direct comparative data is limited. No peptide has been tested directly in a study focused on depression. Their mechanisms differ significantly, however.
The antidepressant effects of Semax appear to be linked to serotonin activation and an increase in BDNF [2], [3]. These mechanisms closely resemble how conventional antidepressants work. The main documented mechanism for Selank is different. It is anxiolytic, acting via GABA modulation and reducing stress-induced pro-inflammatory signalling proteins [11]. This profile aligns more directly with reducing anxiety and stress than with depression-specific mechanisms.
Based on available evidence, Semax has a slightly stronger theoretical justification for depression-related symptoms. Selank's strength lies more clearly in the reduction of anxiety and stress. However, this remains an inference from separate studies rather than a direct comparison.
Is Semax or Selank better for anxiety?
Selank has a more direct and consistent anxiolytic profile. Semax's anti-anxiety effects are more conditional. They clearly appear under the influence of stress or elevated anxiety. But not necessarily at baseline. This distinction is important.
Semax studies show a clear pattern. It normalised anxiety specifically when anxiety was artificially elevated – by CCK-4 or by chronic stress. Under unstressed, normal conditions, it did not produce a measurable effect in at least one study [1]. Selank works differently. It is fundamentally built around an anxiolytic mechanism. Its documented action includes modulation of GABA receptors. It also inhibits enzymes that break down enkephalins, prolonging the activity of the brain's own natural calming opioid-like peptides [11], [12]. These mechanisms are at the core of anxiety reduction. They are not a secondary effect that only appears under specific conditions.
How do Semax and Selank compare mechanistically in the context of anxiety?
The anxiolytic effects of Semax appear to be downstream consequences of broader actions. These include serotonergic activation, increased BDNF, and suppressed stress-related brain activation in the amygdala and hypothalamus [1], [2], [6]. It is not a dedicated anxiolytic mechanism – it's a byproduct of other systems.
Selank's anxiolytic action is more direct. It acts via the GABA system, the brain's primary inhibitory neurotransmitter pathway. It also acts by inhibiting enkephalinase, prolonging the natural calming effects of the brain's own opioid-like peptides [11].
Both peptides inhibit the same enzymes that break down enkephalins in human serum. Semax has an IC₅₀ of 10 micromoles. Selank has an IC50 of 20 micromoles [12]. The IC50 measures the concentration required to achieve 50% inhibition. This means that Semax is actually more potent in this specific mechanism. This is the case even though Selank is the peptide more commonly associated with reducing anxiety in general. This is an interesting detail. It shows that their mechanisms really do overlap, rather than being entirely distinct.
Which is more calming – Semax or Selank?
Selank is generally considered to be more directly calming of the two peptides. This reflects its pharmacological design and the primary focus of its research. Semax is better characterised otherwise. It is an activating and cognitively stimulating nootropic. Its anxiolytic effects appear more pronounced under stress. It does not function as a general sedative.
This distinction is consistent with how the two peptides are generally discussed in Russian pharmacological literature. Semax is a nootropic. Selank is an anxiolytic. Both were developed by the same research group. Both use the same basic glyproline peptide technology. And they share some overlapping mechanisms [13].
Can the combination of Semax and Selank help with anxiety?
The functional connectivity study analysed both peptides in the same 52 healthy participants. Semax and Selank induced both common and distinct effects. These effects appeared on the functional connectivity between the amygdala and the temporal cortex areas [7]. The researchers noted something important. It allowed them, for the first time, to define both general and peptide-specific effects on this brain connection [7].
This discovery suggests something theoretically useful. Combining two peptides could address a wider range of anxiety-related neural circuits than either compound alone. They seem to engage at least partially distinct neural pathways. They also share some common ground. However, one limitation applies. The study did not test the peptides administered together as a combination. It only tested them separately in the same pool of participants. This therefore remains a hypothesis, not direct evidence of combined efficacy.
What is better specifically for social anxiety?
No study has directly tested any of the peptides for social anxiety. Neither in an animal model nor in a clinical context.
Given the more directly anxiolytic, GABA-modulating mechanism of Selank [11], it would theoretically be a more suitable choice. Social anxiety centres on the fear of social appraisal and judgment. The stimulating, dopamine-enhancing properties of Semax [9] could theoretically backfire here. If these properties increase overall arousal or vigilance, they might exacerbate rather than reduce social fears. This is speculative reasoning, however. Neither peptide has been researched in this specific context.
What are users reporting regarding anxiety – Semax or Selank?
User reports are mainly found in online nootropics communities. They cannot be verified or systematically evaluated like data from clinical trials.
These reports generally reflect the mechanistic pattern described above. Selank is more often described as sedating. Semax is more often described as activating — sometimes even mildly anxiogenic in sensitive individuals at higher doses. This fits with its dopaminergic and stimulating properties. These anecdotal patterns align quite well with what pharmacological studies would predict. This grants them some plausibility. However, they remain unverified individual accounts. They should be weighted accordingly.
Disclaimer
This content is for educational and scientific informational purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. It should not be treated as a suggestion to replace established treatment for anxiety or depression. Semax and Selank remain investigational compounds in most countries, including the United States and most European countries. Neither is approved by the FDA or EMA for any medical condition, including anxiety or depressive disorders. Both are approved and clinically used in Russia and some Eastern European countries for other indications. No controlled clinical trials have assessed either compound as a treatment for diagnosed anxiety disorder or clinical depression in humans. Most evidence comes from preclinical animal studies and a very limited number of human studies examining brain connectivity rather than clinical symptoms. Any person experiencing symptoms of anxiety or depression should speak with a qualified healthcare professional or mental health specialist. Do not alter, discontinue, or substitute any prescribed treatment without medical guidance. If you are experiencing thoughts of self-harm or are in emotional crisis, please contact a mental health professional or a crisis support line in your area.
References
[1] Levitskaia, N. G., Vilenskiĭ, D. A., Sebentsova, E. A., Anreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action. News of the Academy of Sciences, Biological Series, (2), 231–237. PMID: 20387390
[2] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 93(6), 661–669. PMID: 17850024
[3] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogues Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
[4] Yatsenko, K. A., Glazova, N. Yu., Inozemtseva, L. S., Andreeva, L. A., Kamensky, A. A., Grivennikov, I. A., Levitskaya, N. G., Dolotov, O. V., & Myasoedov, N. F. (2013). Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats. Doklady Biological Sciences, 453, 353–357. https://doi.org/10.1134/S0012496613060161
[5] Filippenkov, I. B., Stavchansky, V. V., Glazova, N. Yu., Sebentsova, E. A., Remizova, J. A., Valieva, L. V., Levitskaya, N. G., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Antistress action of melanocortin derivatives associated with correction of gene expression patterns in the hippocampus of male rats following acute stress. International Journal of Molecular Sciences, 22(18), 10054. https://doi.org/10.3390/ijms221810054
[6] Umriukhin, P. E., Koplik, E. V., Grivennikov, I. A., Miasoedov, N. F., & Sudakov, K. V. (2001). Gen c-Fos expression in the brains of rats resistant and predisposed to emotional stress following intraperitoneal injection of the ACTH(4-10) analogue — Semax. Journal of Higher Nervous Activity named after I. P. Pavlov, 51(2), 220–227. PMID: 11548604
[7] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
[8] Pae, C. U. (2008). Therapeutic possibility of „Semax” for depression. CNS Spectrums, 13(1), 20–21. https://doi.org/10.1017/s1092852900016102
[9] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[10] Glazova, N. Yu., Manchenko, D. M., Volodina, M. A., Merchieva, S. A., Andreeva, L. A., Kudrin, V. S., Myasoedov, N. F., & Levitskaya, N. G. (2021). Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides, 86, 102114. https://doi.org/10.1016/j.npep.2020.102114
[11] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810
[12] Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Organic Chemistry, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885
[13] Ashmarin, I. P., Samonina, G. E., Lyapina, L. A., Kamenskii, A. A., Levitskaya, N. G., Grivennikov, I. A., Dolotov, O. V., Andreeva, L. A., & Myasoedov, N. F. (2005). Natural and hybrid („chimeric”) stable regulatory glyproline peptides. Pathophysiology, 11(4), 179–185. https://doi.org/10.1016/j.pathophys.2004.10.001